Conor Gallagher, Ph.D.
هذا المحتوى غير متوفر بلغتك بعد.
Conor Gallagher, Ph.D. is Chief Scientific Officer at Revance. His relevance to the botulinum toxin industry comes from current scientific leadership at Revance / Crown Laboratories and Daxxify.
His role complements Thomas Hitchcock, Ph.D., who anchors Revance’s innovation-leadership context. Gallagher is most relevant to Revance’s product-development and medical-science framing after Crown’s acquisition.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Revance |
| Current role | Chief Scientific Officer |
| Company context | Revance within the Crown Laboratories corporate group |
| Relevant company | Revance / Crown Laboratories |
| Relevant brand | Daxxify |
| Official leadership source | Revance: Leadership Team and Board of Directors 🔗 |
Career Notes
Section titled “Career Notes”- Revance identifies Gallagher as Chief Scientific Officer on its current leadership page.
- Revance’s science materials describe work across innovation, medical affairs, clinical studies, and sponsored-trial support.
- Revance describes Daxxify as a peptide-formulated neuromodulator developed and manufactured by Revance.
- Daxxify’s U.S. prescribing information remains the source for product-specific indications, warnings, dosing language, and unit cautions.
Scientific Leadership Context
Section titled “Scientific Leadership Context”Gallagher’s role separates current science leadership from broader promotional discussion around Daxxify. Revance’s product-science framing matters because Daxxify is often discussed through formulation, duration, and innovation language.
That language needs a narrow interpretation. A scientific-leadership connection does not establish that Daxxify is safer, stronger, longer-lasting, or clinically superior to other botulinum toxin products. Product comparisons require product-specific labels, evidence, and market context.
Activity and Public Context
Section titled “Activity and Public Context”Revance’s current public materials position the company across aesthetics, skincare, and therapeutics. For toxin-market interpretation, Gallagher’s most relevant connection is Daxxify and the current Revance science organization supporting product development, medical affairs, and clinical context.
Gallagher pairs naturally with other science and R&D leaders, including Darin J. Messina, Ph.D. at AbbVie / Allergan Aesthetics and Thomas Hitchcock, Ph.D. at Revance.